Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial.

John B BuseStephen C BainJohannes F E MannMichael A NauckSteven E NissenStuart PocockNeil R PoulterRichard E PratleyMartin LinderTea Monk FriesDavid D ØrstedBernard Zinmannull null

Published in: Diabetes care (2020)

These analyses identify HbA1c and, to a lesser extent, UACR as potential mediators of the CV effects of liraglutide. Whether either is a marker of an unmeasured factor or a true mediator remains a key question that invites further investigation.

Keyphrases

study protocol
phase iii
clinical trial
phase ii
social support
randomized controlled trial
human health
open label
risk assessment
depressive symptoms
placebo controlled